PredictImmune Awarded £4.3M to Evaluate Ability of Prognostic Test to Guide Crohn’s Treatment

PredictImmune Awarded £4.3M to Evaluate Ability of Prognostic Test to Guide Crohn’s Treatment
PredictImmune has received a £4.3 million (US$5.85 million) grant to fund a prospective clinical trial to determine if its prognostic biomarker test can help personalize treatment strategies for patients with Crohn’s disease, a type of inflammatory bowel disease (IBD). This funding is being provided by the Wellcome Trust, a nonprofit that supports health and medical research. The trial, titled "Predicting Outcomes for Crohn’s disease using a Molecular Biomarker" (PROFILE), is sponsored by Cambridge University Hospital NHS Foundation Trust and the University of Cambridge in the U.K. PredictImmune’s prognostic test is based on a molecular signature detectable in CD8 T-cells, a specialized type of immune cell. It consists of a simple blood analysis for specific genetic markers of these cells, allowing both diagnosis and, for the first time, prediction of disease progression. Using this test, patients with a higher chance of experiencing a severe, relapsing form of the disease can be identified early. Predicting long-term disease severity in Crohn's patients may help reduce suffering caused by over- or under-treatment. This prognostic test was already validated in patients with Crohn’s disease and ulcerative colitis. Several studies demonstrated the clinical and economic benefits of the biomarker test in determining first-line treatment based on prediction of the disease course. The PROF
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *